BioNTech SE (NASDAQ: BNTX) saw its American depositary shares tumble 6.6% on Friday after the company announced the discontinuation of a Phase 2 study evaluating its investigational mRNA vaccine for colorectal cancer. The stock was trading at $104.09 as of 10:05 a.m. EDT, wiping out approximately $1.8 billion in market capitalization from its June valuation.
The decision to halt the trial, which was testing autogene cevumeran in patients with high-risk colorectal cancer, came at the recommendation of an independent data safety monitoring board. The board noted a numerical imbalance in overall survival between study groups and determined that continuing the study would be unlikely to alter the efficacy conclusions.
The trial, identified as NCT05968326, enrolled patients who had undergone surgery for stage II high-risk or stage III tumors and who continued to test positive for circulating tumor DNA, indicating residual disease risk. The program was being developed in collaboration with Genentech, a subsidiary of Roche (RHHBY).
This setback is a significant blow to BioNTech's oncology pipeline, but it does not necessarily derail the company's broader cancer research efforts. BioNTech continues to invest heavily in its oncology portfolio, with research and development expenses for the second quarter reaching €551 million, which is 5.2 times the revenue of €105.6 million reported for the same period.
The company's net loss for the quarter widened to €820.8 million, more than double the prior year's figure, reflecting the substantial investment in its pipeline. Despite these losses, BioNTech maintains a robust balance sheet with €16.63 billion in cash and securities as of June 30, providing flexibility to reallocate capital to other promising programs.
Looking ahead, BioNTech has projected adjusted R&D expenses of €2.0 billion to €2.3 billion for the full year, while also trimming its 2026 revenue forecast to €1.6 billion–€1.9 billion. The company's ability to sustain its pipeline and weather such setbacks will be closely watched by investors.
Analysts remain cautiously optimistic, with a consensus rating of Buy from twenty analysts and an average price target of $121.51, suggesting potential upside from current levels. However, the halt of the colorectal cancer study adds uncertainty to the pipeline valuation and could lead to downward revisions if further setbacks occur.
Investors will now focus on BioNTech's other oncology programs and its progress in personalized immunotherapy, as the company seeks to diversify its revenue streams beyond its COVID-19 vaccine partnership.
